PATENT CLAIM ANALYSIS

Application Number: 16030204
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["424", "186100"]

Abstract:
The invention relates to a recombinant adenovirus that has an oncolytic effect in a cancer cell. By modulating the level and type of splice isoforms of the E 1 B gene product, expressed from the E 1 B gene, the oncolytic activity of such viruses can be enhanced. The invention provides a recombinant adenovirus in which the proportion of the E 1 B-156R isoform is increased relative to wild-type levels. Such a recombinant adenovirus may selectivity replicate in cancer cells, thereby killing cancer cells whilst sparing normal cells.

Claim (Index 43):
The method of  claim 34 , wherein the E1B-156R isoform has a polynucleotide sequence that has at least 80% sequence identity to SEQ ID NO: 2; and/or the E1B-156R isoform has a polypeptide sequence that has at least 80% sequence identity to SEQ ID NO: 3.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 95.0
- Lexical Diversity: 1.61017
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14648661', '13254825', '10669768', '09351778', '12561016']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7541999751849819
- 35 USC 102 Novelty (BERT): 0.7084005432646967
- Combined Prediction Score: 0.7496200319929535
- Mean Citation Score: 516.8528660000002
- Max Citation Score: 883.802
- Similarity Product: 712.2404718593359

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test